The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies

Jia Ling Li, Guo Liang Shen, Maria Ana Ghetie, Richard D. May, Mark Till, Victor Ghetie, Jonathan W. Uhr, George Janossy, Philip E. Thorpe, Peter Amlot, Ellen S. Vitetta

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


The CD22 antigen is expressed on the surface of normal human B cells and some neoplastic B cell lines and tumors. Previous cross-blocking studies using a panel of monoclonal anti-CD22 antibodies have defined four epitope groups, termed A-D. In the present studies, we have further dissected the epitopes recognized by four monoclonal anti-CD22 antibodies using immunopre-cipitation and cross-blocking techniques, immunofluorescence analyses with a variety of cell lines, and immunoperoxidase analyses of 36 normal human tissues. Two of the antibodies, HD6 and RFB4, have been described previously, and two, UV22-1 and UV22-2, are described in this report. Our studies indicate that the four monoclonal antibodies show unexpected complexities in their reactivity with CD22+ and CD22- cells and their reactivity with solubilized CD22 molecules. The four antibodies, which recognize epitopes defined previously as CD22-A and CD22-B, further subdivide these epitope clusters into four determinants, A1, A2, B1, and B2. Furthermore, only two of the antibodies, RFB4 and UV22-2, are B cell-specific. In summary, our data indicate that RFB4 and UV22-2 would be the antibodies of choice for constructing immunotoxins to treat B cell tumors.

Original languageEnglish (US)
Pages (from-to)85-99
Number of pages15
JournalCellular Immunology
Issue number1
StatePublished - Jan 1989

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies'. Together they form a unique fingerprint.

Cite this